What are the adverse drug reactions of bevacizumab?

Bevacizumab Adverse Drug Reactions

Bevacizumab carries significant class-specific toxicities that require vigilant monitoring, with the most clinically important being gastrointestinal perforation (rare but potentially fatal), hemorrhage, hypertension, proteinuria, arterial thromboembolic events, and impaired wound healing. 1

Life-Threatening and Serious Adverse Reactions

Gastrointestinal Complications

• Gastrointestinal perforation occurs in approximately 0.3-2.4% of patients and is the most feared complication, with a 7.1% fatality rate among treatment-related deaths 1
• Risk factors include extensive prior intra-abdominal surgery (especially peritoneal stripping/debulking), though an intact primary tumor does NOT increase risk 1
• FDA black box warning for necrotizing fasciitis (sometimes fatal), typically secondary to wound healing complications, GI perforation, or fistula formation 1, 2
• Fistulae formation, particularly anal fistula (4% in cervical cancer patients) 3

Hemorrhagic Events

• Hemorrhage accounts for 23.5% of treatment-related fatalities 1
• Ranges from minor mucosal bleeding (epistaxis is common, occurring in 27% of renal cell carcinoma patients) to life-threatening events 3
• Cerebral hemorrhage and intracranial bleeding are particularly concerning in patients with brain metastases, though the PASSPORT study showed acceptable safety when brain metastases were previously treated and stable 4
• Pulmonary hemorrhage led to early trial exclusions in squamous NSCLC patients

Cardiovascular Toxicity

• Hypertension is the most common adverse event (occurs in 6-28% depending on indication) 1, 3

  • Grade 3-4 hypertension: 9-12% in colorectal cancer, 11% in cervical cancer 1, 3
  • Requires routine blood pressure monitoring throughout treatment
  • Particularly elevated risk in patients ≥65 years 1

• Arterial thromboembolic events (stroke, MI, TIA) show increased incidence, especially in elderly patients (≥65 years) 1, 2

• Venous thromboembolism: Deep vein thrombosis (9% vs 5% with chemotherapy alone), pulmonary embolism 1

• Congestive heart failure: 1-4% incidence, higher (4%) in patients with prior anthracycline exposure 3

  • 10% of patients experienced LVEF decline ≥20% or to <50% when combined with anthracyclines 3

Renal Toxicity

• Proteinuria occurs in 7-20% of patients 1, 3
• Monitor urine protein every 3-4 weeks; discontinue if nephrotic syndrome develops 5

Neurological Events

• Posterior reversible encephalopathy syndrome (PRES) - rare but serious 3
• Hypertensive encephalopathy shows high signal in real-world data despite being listed as rare 6

Common Non-Life-Threatening Adverse Reactions

Hematologic

• Neutropenia: 8-21% (Grade 3-4) 1, 3
• Lymphopenia: 6-12% 3
• Does NOT increase chemotherapy-related neutropenia when added to regimens 7

Gastrointestinal (Non-Perforation)

• Diarrhea: 18-34% (Grade 3-4) 1
• Stomatitis/mucosal inflammation: 13-15% 3
• Abdominal pain: 8-12% 1, 3

General

• Fatigue/asthenia: 10-19% (Grade 3-4) 1, 3
• Headache: common, occurs in 24% 3

Dermatologic

• Palmar-plantar erythrodysesthesia: 4.5% (Grade 3-4) when combined with certain chemotherapies 3

Wound Healing Complications

Critical timing considerations:

• 13% wound healing complications when major surgery performed while receiving bevacizumab vs 3.4% with chemotherapy alone 1
• Safe approach: Stop bevacizumab at least 5-8 weeks before elective surgery 1, 5
• After surgery: Wait at least 4-6 weeks before initiating bevacizumab 1
• When properly timed (≥6 weeks between bevacizumab and surgery), wound complications drop to 1.3% vs 0.5% with chemotherapy alone 1

Treatment-Related Mortality

Meta-analysis data shows increased treatment-related mortality (RR 1.33,95% CI 1.02-1.73, p=0.04) compared to chemotherapy alone 1, 8:

• Hemorrhage: 23.5% of fatalities
• Neutropenia: 12.2% of fatalities
• GI perforation: 7.1% of fatalities

Ovarian Failure

• Bevacizumab causes ovarian failure in reproductive-age women 3
• Counsel patients about fertility preservation before treatment initiation

Population-Specific Risks

Elderly Patients (≥65 years)

• Significantly higher risk of arterial thromboembolic events 1, 2
• Increased stroke risk 1

Patients with Prior Surgery

• Extensive intra-abdominal surgery (peritoneal stripping) is a major risk factor for GI perforation 1, 2
• Peritoneal debulking surgery dramatically increases perforation risk 1

Real-World Safety Signals

Recent pharmacovigilance data 6, 9 identified additional concerns:

• Nasal septum perforation (PRR = 47.5) - higher than expected from trials
• Necrotizing fasciitis (PRR = 20.3) - requires immediate recognition
• Limb decortication syndrome (PRR = 2926) - extremely high signal
• 96 unique ADRs identified in case reports, with 28 (29%) being non-label ADRs 9

Monitoring Algorithm

Baseline: Blood pressure, urinalysis for protein, CBC, comprehensive metabolic panel, cardiac assessment if anthracycline history

During treatment:

• Blood pressure: Every visit
• Urinalysis: Every 3-4 weeks 5
• CBC: Per chemotherapy protocol
• Clinical assessment for bleeding, neurologic symptoms, abdominal pain: Every visit

Discontinuation criteria:

• Nephrotic syndrome or persistent proteinuria >2+ 5
• GI perforation
• Grade 4 hemorrhage
• Life-threatening arterial or venous thromboembolism
• Symptomatic CHF
• PRES
• Wound dehiscence requiring intervention